Publications by authors named "Mark Baer"

Claim this Profile
T
The Highly Productive C1 Expression System as a Host for Rapid Development of Influenza Vaccines.
Gabor Keresztes, Mark Baer, Mark R Alfenito, Theo C Verwoerd, Andriy Kovalchuk

Vaccines (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high affinity recombinant antibody to the human EphA3 receptor with enhanced ADCC activity.
Nenad Tomasevic, Kenneth Luehrsen, Mark Baer, Varghese Palath, David Martinez

Growth Factors· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Mary E Vail, Carmel Murone, April Tan, Linda Hii, Degu Abebe, Mark Baer

Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
Fanny Legrand, Nenad Tomasevic, Olga Simakova, Chyi-Chia Richard Lee, Zengfang Wang, Mark Baer

J Allergy Clin Immunol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Eric Padron, Jeffrey S Painter, Sateesh Kunigal, Adam W Mailloux, Kathy McGraw, Mark Baer

Blood· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody to granulocyte macrophage colony-stimulating factor reduces the number of activated tissue macrophages and improves left ventricular function after myocardial infarction in a rat coronary artery ligation model.
Robert S Kellar, Jordan J Lancaster, Hoang M Thai, Elizabeth Juneman, Nicholle M Johnson, Mark Baer

J Cardiovasc Pharmacol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
Mark Baer, Teiji Sawa, Peter Flynn, Kenneth Luehrsen, David Martinez

Infect Immun· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-resolution characterization of antibody fragment/antigen interactions using Biacore T100.
Giuseppe A Papalia, Mark Baer, Kenneth Luehrsen, Helena Nordin, Peter Flynn

Anal Biochem· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages.
Jennifer Wessells, Mark Baer, Howard A Young, Estefania Claudio, Keith Brown

J Biol Chem· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of CCAAT/enhancer-binding protein (C/EBP) activator proteins by heterodimerization with C/EBPgamma (Ig/EBP).
Sara E Parkin, Mark Baer, Terry D Copeland, Richard C Schwartz, Peter F Johnson

J Biol Chem· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis